Allison C Rosenthal
Overview
Explore the profile of Allison C Rosenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daryanani A, Abbasi M, Gomez Ardila M, Tellez-Garcia E, Garzon-Dangond J, Lin Y, et al.
Cardiooncology
. 2024 Dec;
10(1):91.
PMID: 39709512
Background: CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune...
2.
Okcu I, Wang Y, Bock A, Zhou J, Alhaj Moustafa M, Tun H, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Sep;
25(2):116-123.
PMID: 39232904
Background: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon type of aggressive B-cell non-Hodgkin lymphoma. PMBCL shares some clinical and biologic features with nodular sclerosis classic Hodgkin lymphoma (cHL)....
3.
Khurana A, Rosenthal A, Mohty R, Gaddam M, Bansal R, Hathcock M, et al.
Blood Cancer J
. 2024 Aug;
14(1):136.
PMID: 39134524
No abstract available.
4.
Laughlin B, Van Der Walt C, Mangold A, Breen W, Rosenthal A, Lester S, et al.
Adv Radiat Oncol
. 2024 Jun;
9(7):101502.
PMID: 38846486
Purpose: Low-dose total skin electron beam therapy (TSEBT) is a proven treatment for managing cutaneous T-cell lymphoma (CTCL) and Sezary syndrome with skin burden. We performed a retrospective comparison of...
5.
Laughlin B, Zaniletti I, Foster M, Lucido J, Mangold A, Rosenthal A, et al.
Anticancer Res
. 2024 Mar;
44(4):1491-1497.
PMID: 38537978
Background/aim: Total skin electron beam therapy (TSEBT) is an effective treatment for managing cutaneous T-cell lymphoma (CTCL), but may result in unnecessary toxicity. With the production of a custom rolling...
6.
Bi L, Rosenthal A, Kuo P, Yang M
J Nucl Med Technol
. 2023 Oct;
52(2):177-178.
PMID: 37852645
We present the case of a young woman with Hodgkin lymphoma exhibiting physiologic F-FDG uptake in brown adipose tissue and lactating breast on consecutive F-FDG PET/CT scans. Both entities are...
7.
Jacobson C, Rosenthal A, Arnason J, Agarwal S, Zhang P, Wu W, et al.
Blood Adv
. 2023 Jul;
7(21):6790-6799.
PMID: 37399456
Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide...
8.
Wiedmeier-Nutor J, Iqbal M, Rosenthal A, Bezerra E, Garcia-Robledo J, Bansal R, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Apr;
23(6):456-462.
PMID: 37003846
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma...
9.
Rosenthal A, Munoz J, Villasboas J
Clin Epigenetics
. 2023 Mar;
15(1):39.
PMID: 36871057
Background: Advances in understanding of cancer biology, genomics, epigenomics, and immunology have resulted in development of several therapeutic options that expand cancer care beyond traditional chemotherapy or radiotherapy, including individualized...
10.
Huntington S, Schuster S, Ding W, Koehler A, Brander D, Rosenthal A, et al.
Am J Hematol
. 2023 Feb;
98(5):739-749.
PMID: 36810799
Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase inhibitors (BTKi) with inhibitors of mammalian target of rapamycin (mTOR) and immunomodulatory agents (IMiD). We conducted a phase 1,...